CADL

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics Plans Key BLA Submission and Strategic Partnerships

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Candel Therapeutics is preparing to submit a Biologics License Application for aglatimagene in prostate cancer by Q4 2026, bolstered by a partnership with EVERSANA for its launch. Promising trial results in lung and prostate cancers position Candel favorably for upcoming milestones, particularly the AUA 2026 presentations which will likely bolster investor confidence.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Candel Therapeutics plans BLA submission for aglatimagene in Q4 2026.</li><li>A partnership with EVERSANA will support commercial launch in prostate cancer.</li><li>Positive trial data shows extended survival in NSCLC patients with aglatimagene.</li><li>Upcoming data presentation at AUA 2026 for prostate cancer trial results.</li><li>Candel has $194.8 million in cash, funding operations through Q1 2028.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>EVERSANA (N/A)</strong>: Their partnership will significantly enhance Candel&#039;s commercial strategy.</li><li><strong>RTW Investments, LP (N/A)</strong>: Provided $100 million royalty funding, strengthening Candel&#039;s financial position.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news falls under &#039;Corporate Developments&#039; as it involves significant milestones in regulatory submissions and commercial partnerships, which are critical to Candel&#039;s business strategy and market perception. These developments are likely to affect CADL&#039;s stock performance significantly in the near term.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>BLA submission in Q4 2026 could trigger significant investor interest.</li><li>Strong clinical trial results could lead to increased stock price estimates.</li><li>Partnership with EVERSANA enhances commercial prospects for aglatimagene.</li><li>Presentation of new clinical data at AUA 2026 could attract new investors.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Cash position of $194.8 million as of March 31, 2026.</li><li>BLA for aglatimagene planned for submission in Q4 2026.</li><li>Partnership with EVERSANA announced to support market entry.</li><li>Phase 3 trial results for prostate cancer to be presented at AUA 2026.</li><li>Initiation of pivotal phase 3 NSCLC trial expected in Q2 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in CADL for potential upside leading to BLA submission and trial results in 2026.</p>
  </section>
</section>


<article>
    <h2>Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights</h2>
    <p>NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ: <a href="https://www.benzinga.com/quote/CADL">CADL</a>), a clinical-stage biopharmaceutical company, has announced its financial results for the first quarter ending March 31, 2026, alongside significant updates on its clinical and commercial programs. This quarter highlights substantial progress in advancing its lead immunotherapy programs and preparations for upcoming regulatory filings.</p>
    
    <h3>Key Financial Highlights</h3>
    <p>Candel Therapeutics has reported cash and cash equivalents of <strong>$194.8 million</strong> as of March 31, 2026. This funding is projected to support the company’s operations through Q1 2028, which includes activities crucial to the potential commercial launch of its lead product, aglatimagene besadenovec (CAN-2409), in 2027.</p>
    
    <h3>Progress in Clinical Development of Aglatimagene (CAN-2409)</h3>
    <p>The focus of Candel’s ongoing efforts remains on the planned submission of a Biologics License Application (BLA) for aglatimagene in localized, intermediate- to high-risk prostate cancer by Q4 2026. Candel is also preparing for the presentation of important clinical data during the American Urological Association (AUA) 2026 Annual Meeting, occurring this May.</p>
    
    <h4>Upcoming Milestones</h4>
    <ul>
        <li>Aglatimagene is scheduled for BLA submission in Q4 2026.</li>
        <li>Follow-up data from the phase 3 trial for prostate cancer will be presented at the AUA 2026 Annual Meeting in Washington, D.C.</li>
        <li>A pivotal phase 3 clinical trial for aglatimagene in patients with progressive, metastatic non-small cell lung cancer (NSCLC) is planned to commence in Q2 2026.</li>
    </ul>
    
    <h3>Clinical Program Developments and Data Highlights</h3>
    <p>Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel, emphasized that "the quarter was marked by strong execution across our lead clinical programs and commercial readiness efforts." Candel continues to build on its clinical pipeline with promising data indicating the durability of response from aglatimagene therapy:</p>
    
    <ul>
        <li>In a phase 2a trial for NSCLC, a remarkable <strong>50%</strong> of patients treated per-protocol survived beyond 24 months, illustrating the long-term efficacy of aglatimagene despite prior inadequate response to immune checkpoint inhibitors (ICI).</li>
        <li>For patients surviving beyond 24 months, <strong>85%</strong> had baseline PD-L1 tumor proportion scores below 50%, suggesting aglatimagene may turn non-responders into responders.</li>
        <li>The median overall survival (mOS) in this cohort was reported at <strong>25.4 months</strong>, further supporting the potential of aglatimagene in precision medicine applications for NSCLC.</li>
    </ul>
    
    <h3>Strategic Partnerships and Commercial Readiness</h3>
    <p>Candel is partnering with leading organizations like EVERSANA® and IDEA Pharma to enhance its commercial strategy for the potential U.S. launch of aglatimagene. This partnership is aimed at providing a scalable approach that will facilitate a successful and timely introduction of the therapy upon approval.</p>
    
    <h3>Looking Ahead</h3>
    <p>The upcoming months are critical for Candel Therapeutics as it continues to progress towards its BLA filing while simultaneously advancing its clinical trials across various cancer indications. The company is poised to make significant strides in improving treatment options for patients with localized prostate cancer and advanced NSCLC, driven by the promising results seen so far with aglatimagene (CADL).</p>
    
    <h3>Conclusion</h3>
    <p>Candel Therapeutics' recent financial report and corporate updates reflect robust company momentum and a solid foundation for ongoing and future initiatives. As it approaches key regulatory submissions and potential product launches, investors and stakeholders remain focused on the transformative potential of its lead immunotherapy, aglatimagene, in the oncology landscape.</p>
</article>

Candel Therapeutics is preparing to submit a Biologics License Application for aglatimagene in prostate cancer by Q4 2026, bolstered by a partnership with EVERSANA for its launch. Promising trial results in lung and prostate cancers position Candel favorably for upcoming milestones, particularly the AUA 2026 presentations which will likely bolster investor confidence.

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News